Chloroquine D5
(Synonyms: 氯喹 d5) 目录号 : GC60700An internal standard for the quantification of chloroquine
Cas No.:1854126-41-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Chloroquine-d5 is intended for use as an internal standard for the quantification of chloroquine by GC- or LC-MS. Chloroquine is an aminoquinoline that is an inhibitor of autophagy and has antimalarial, anti-inflammatory, anticancer, and antiviral activities.1,2,3,4,5 Chloroquine inhibits autophagosome-lysosome fusion in HeLa cells when used at a concentration of 100 ?M.1 It is active against the chloroquine-sensitive GC03 strain of P. falciparum (IC50 = 29.2 nM) but has decreased activity against mutant pfcrt P. falciparum (IC50s = 100-150 nM).3 Chloroquine prevents infection by severe acute respiratory coronavirus 2 (SARS-CoV-2) in Vero cells (EC50 = 1.13 ?M) but does not inhibit SARS-CoV replication in the lungs in a mouse model of SARS-CoV infection.5,6 It inhibits the growth of human SSC25 and CAL 27 oral squamous cell carcinoma cells (IC50s = 29.9 and 17.3 ?M, respectively), as well as A498, SN12C, RXF 393, and 769-P renal cancer cells (IC50s = 16, 62, 81, and 25 ?M, respectively).4,7 It reduces tumor growth in a CAL 27 mouse xenograft model and a 4T1 mouse allograft model when administered at a dose of 50 mg/kg.4,8 Formulations containing chloroquine have been used in the prevention of malaria, as well as the treatment of rheumatoid arthritis and systemic lupus erythematosus (SLE), and have been associated with cardiotoxicity and myopathy.
1.Mauthe, M., Orhon, I., Rocchi, C., et al.Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusionAutophagy14(8)1435-1455(2018) 2.Plantone, D., and Koudriavtseva, T.Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: A mini-reviewClin. Drug Investig.38(8)653-671(2018) 3.Sidhu, A.B.S., Verdier-Pinard, D., and Fidock, D.A.Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutationsScience298(5591)210-213(2002) 4.Jia, L., Wang, J., Wu, T., et al.In vitro and in vivo antitumor effects of chloroquine on oral squamous cell carcinomaMol. Med. Rep.16(5)5779-5786(2017) 5.Wang, M., Cao, R., Zhang, L., et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30(3)269-271(2020) 6.Barnard, D.L., Day, C.W., Bailey, K., et al.Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c miceAntivir. Chem. Chemother.17(5)275-784(2006) 7.Grimaldi, A., Santini, D., Zappavigna, S., et al.Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cellsCancer Biol. Ther.16(4)567-579(2015) 8.Jiang, P.-D., Zhao, Y.-L., Deng, X.-Q., et al.Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancerBiomed. Pharmacother.64(9)609-614(2010)
Cas No. | 1854126-41-2 | SDF | |
别名 | 氯喹 d5 | ||
Canonical SMILES | CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCN(CC)C([2H])([2H])C([2H])([2H])[2H] | ||
分子式 | C18H21D5ClN3 | 分子量 | 324.9 |
溶解度 | DMSO : 50 mg/mL (153.89 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.0779 mL | 15.3894 mL | 30.7787 mL |
5 mM | 0.6156 mL | 3.0779 mL | 6.1557 mL |
10 mM | 0.3078 mL | 1.5389 mL | 3.0779 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。